跳转到内容

乙酰水杨酸雌二醇

维基百科,自由的百科全书
(重定向自C27H30O5
乙酰水杨酸雌二醇
臨床資料
其他名稱Estradiol 3-acetylsalicylate; Acetylsalicylate estradiol
给药途径口服
藥物類別雌激素药物英语Estrogen (medication); 雌激素酯英语Estrogen ester
识别信息
  • [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] 2-acetyloxybenzoate
CAS号111111-98-9  checkY
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
化学信息
化学式C27H30O5
摩尔质量434.53 g·mol−1
3D模型(JSmol
  • CC(=O)OC1=CC=CC=C1C(=O)OC2=CC3=C(C=C2)[C@H]4CC[C@]5([C@H]([C@@H]4CC3)CC[C@@H]5O)C
  • InChI=1S/C27H30O5/c1-16(28)31-24-6-4-3-5-22(24)26(30)32-18-8-10-19-17(15-18)7-9-21-20(19)13-14-27(2)23(21)11-12-25(27)29/h3-6,8,10,15,20-21,23,25,29H,7,9,11-14H2,1-2H3/t20-,21-,23+,25+,27+/m1/s1
  • Key:KNJUTXJFANOVGR-HXVSAZQXSA-N

乙酰水杨酸雌二醇(英語:Estradiol acetylsalicylate),即3-乙酰水杨酸雌二醇,是一种合成雌激素雌激素酯英语Estrogen ester,具体而言是指雌二醇的3号碳的乙酰水杨酸(阿司匹林)。该药物于20世纪80年代末被描述,但从未上市[1][2][3][4][5]。在狗中,乙酰水杨酸雌二醇的口服生物利用度比未修饰的雌二醇高17倍[1][4]。然而,一个随后的研究发现,雌二醇和乙酰水杨酸雌二醇的口服生物利用度在大鼠中没有显着差异(分别为4.3%和4.2%),暗示该药物存在很大的物种差异[2][4][6]

参见

[编辑]

参考来源

[编辑]
  1. ^ 1.0 1.1 Hussain MA, Aungst BJ, Shefter E. Prodrugs for improved oral beta-estradiol bioavailability. Pharmaceutical Research. 1988-01, 5 (1): 44–47. PMID 3244608. S2CID 7308414. doi:10.1023/A:1015863412137. 
  2. ^ 2.0 2.1 Lokind KB, Lorenzen FH, Bundgaard H. Oral bioavailability of 17β-estradiol and various ester prodrugs in the rat. International Journal of Pharmaceutics. 1991, 76 (1–2): 177–182. ISSN 0378-5173. doi:10.1016/0378-5173(91)90356-S. 
  3. ^ Kuhnz W, Blode, Zimmerman H. Pharmacokinetics of Exogenous Natural and Synthetic Estrogens and Antiestrogens. Oettel M, Schillinger E (编). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Handbook of Experimental Pharmacology. 135 / 2. Springer Science & Business Media. 2012-12-06: 263–. ISBN 978-3-642-60107-1. doi:10.1007/978-3-642-60107-1_15. 
  4. ^ 4.0 4.1 4.2 Aungst BJ, Matz N. Prodrugs to Reduce Presystemic Metabolism. Stella V, Borchardt R, Hageman M, Oliyai R, Maag H, Tilley J (编). Prodrugs: Challenges and Rewards. Biotechnology: Pharmaceutical Aspects. Springer Science & Business Media. 2007-08-26: 347–. ISBN 978-0-387-49785-3. doi:10.1007/978-0-387-49785-3_8. 
  5. ^ Moridani MY. Reducing Presystemic Drug Metabolism. Rautio J (编). Prodrugs and Targeted Delivery: Towards Better ADME Properties. John Wiley & Sons. 2011-01-11: 218–. ISBN 978-3-527-63318-0. 
  6. ^ Hansen J, Mørk N, Bundgaard H. Phenyl carbamates of amino acids as prodrug forms for protecting phenols against first-pass metabolism. International Journal of Pharmaceutics. 1992, 81 (2–3): 253–261. ISSN 0378-5173. doi:10.1016/0378-5173(92)90017-V.